The Medical Letter on Drugs and Therapeutics
Ivermectin (Sklice) Topical Lotion for Head Lice
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the antiparasitic drug ivermectin in a 0.5% lotion (Sklice – Sanofi Pasteur) as a single-use topical treatment for head lice in patients ≥6 months old. Oral ivermectin (Stromectol – Merck) is effective for treatment of head lice resistant to other therapies, but it has not been approved by the FDA for this indication.1

MECHANISM OF ACTION — Ivermectin is derived from the fermentation of Streptomyces avermitilis, a soil-dwelling actinomycete. It binds to glutamate-gated chloride channels in invertebrates, inducing paralysis and death in the parasites. Ivermectin lotion 0.5% is not directly ovicidal (hatchability does not decrease), but lice that hatch from treated eggs die within 48 hours after hatching.2

PHARMACOKINETICS — An unpublished study of 20 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ivermectin (Sklice) Topical Lotion for Head Lice
Article code: 1396b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian